Tesamorelin vs Ipamorelin: Which Is Better for Fat Loss? BioHarmony head-to-head comparison
Head-to-Head Comparison

Tesamorelin vs Ipamorelin: Which Is Better for Fat Loss?

Should I take tesamorelin or ipamorelin?

Reviewed 09/07/2026

Both score 6.2, and that tie hides the real picture. Tesamorelin outscores ipamorelin on all 16 shared use cases and carries Phase 3 trials on visceral and liver fat. Ipamorelin's only completed human efficacy trial failed. Price is the honest argument for ipamorelin, at roughly a tenth the monthly cost.

  • Both land at 6.2 overall, yet tesamorelin scores higher on every one of the 16 shared use cases.
  • Tesamorelin's evidence dimension scores 4.6 against ipamorelin's 3.3, built on two Phase 3 HIV lipodystrophy trials plus a 2026 meta-analysis of five RCTs.
  • Ipamorelin has zero human efficacy RCTs for anything it is sold for. Its one completed trial, in postoperative ileus, missed its endpoint at p=0.15.
  • Cost is the real split: an estimated $250 to $500 a month against $25 to $60.
  • Tesamorelin's benefits regress after you stop, which is why its durability dimension scores 1.5. Treat it as chronic therapy, not a cycle.
  • Both are prohibited in tested sport at all times, tesamorelin as a growth hormone-releasing factor and ipamorelin under WADA S2.

At a Glance

Tesamorelin
Option A

Tesamorelin

6.2 / 10 Worth trying
Upside
  • Efficacy 4.3
  • Breadth 4.0
  • Evidence 4.6
  • Speed 2.5
  • Durability 1.5
  • Bioindividuality 4.0
Downside
  • Safety Risk 1.9
  • Side Effects 2.3
  • Cost 4.0
  • Effort 2.5
  • Opportunity Cost 2.5
  • Dependency 3.5
  • Reversibility 2.0
Best at:
  • Body Composition 7.5
  • Hormonal 7.5
  • Metabolic Health 7.0
  • Liver Detox 6.5

Stabilized GHRH analog, FDA-approved for HIV-associated abdominal lipodystrophy. BioHarmony 6.2, worth trying.

Read full BioHarmony report →

Ipamorelin
Option B

Ipamorelin

6.2 / 10 Worth trying
Upside
  • Efficacy 3.3
  • Breadth 3.3
  • Evidence 3.3
  • Speed 3.2
  • Durability 2.4
  • Bioindividuality 3.3
Downside
  • Safety Risk 1.8
  • Side Effects 1.6
  • Cost 2.6
  • Effort 3.0
  • Opportunity Cost 2.2
  • Dependency 2.6
  • Reversibility 1.6
Best at:
  • Sleep Quality 2.8
  • Recovery Repair 2.4
  • Bone Joint 2.2
  • Injury Recovery 2.1

Selective ghrelin-receptor agonist with no approved indication. BioHarmony 6.2, worth trying.

Read full BioHarmony report →

Head-to-Head Verdict

Use CaseWinnerRationale
Body CompositionTesamorelinTesamorelin 7.5 against ipamorelin's 2.0, the widest gap in the matrix. Falutz 2007 was the landmark Phase 3 trial showing visceral fat reduction with subcutaneous fat largely preserved, and Badran 2026 pooled five RCTs finding reductions in visceral fat, trunk fat, hepatic fat percentage and waist circumference with increased lean mass. Ipamorelin has no human body composition trial.
Metabolic HealthTesamorelinTesamorelin 7.0 against 1.6. Stanley 2012 pooled responder data and found visceral fat responders had better triglyceride and glucose-marker patterns than nonresponders, and Stanley 2019 reduced liver fat across 61 people with HIV-associated fatty liver disease over 12 months. Ipamorelin's metabolic case is an inference from growth hormone biology.
Anti InflammatoryTesamorelinTesamorelin 5.0 against 1.4. Stanley 2011 tracked inflammatory and fibrinolytic markers in 410 HIV-infected patients and tied the changes to visceral fat reduction. That is a marker study in a specific population rather than a general anti-inflammatory result, and it is still the only measured inflammation data in this comparison.
GeriatricTesamorelinTesamorelin 6.0 against 1.8. Baker 2012 ran a 20-week randomized trial of GHRH analog therapy in older adults and people with mild cognitive impairment, and Adrian 2019 found improved trunk muscle area and density in responders. Ipamorelin's closest evidence is Jimenez-Reina 2002, which studied chronic dosing in young female rats.
Muscle GrowthTesamorelinTesamorelin 4.5 against 1.9, on thin evidence for both. Adrian 2019 is an exploratory secondary analysis where responders showed better trunk muscle area and density than placebo. Ipamorelin's parent-class context comes from Sinha 2020 on growth-hormone secretagogues in hypogonadal males, where the best data belongs to other compounds in the class.
Cognition FocusTieTesamorelin's subrating is 6.5 against 1.3, and the trial record does not support that gap. Ellis 2025 ran an open-label randomized phase 2 trial in people with HIV and abdominal obesity, and neurocognitive benefit did not differ significantly from standard care. Baker 2012 was positive but tested a GHRH analog protocol in a different population, and ipamorelin has nothing at all here.
Sleep QualityTieTesamorelin 4.5 against 2.8, and neither side has a sleep trial. The only sleep evidence in either citation record is Weikel 2003, where ghrelin infusion increased slow-wave sleep in 7 men, which is a receptor proxy for ipamorelin rather than a study of it. Better sleep is the most common claim made for ipamorelin and the least supported.
Recovery RepairTieTesamorelin 4.5 against 2.4, with no human recovery trial on either side. Tesamorelin's supporting data is a secondary muscle-area analysis in HIV patients. Ipamorelin's is Aagaard 2009, where the peptide cut glucocorticoid-induced hepatic nitrogen wasting by about 20 percent in rats. Rodent nitrogen balance is not a training-recovery result.
Bone JointTieTesamorelin 3.5 against 2.2, and this is the row where ipamorelin has more supporting work, all of it in animals. Johansen 1999 found longitudinal bone growth in rats, Svensson 2000 found increased bone mineral content through bone size rather than density in adult female rats, and Andersen 2001 found it counteracted glucocorticoid-induced loss of bone formation. Tesamorelin has no bone data.

Cost Comparison

InterventionMonthly CostNotes
Tesamorelin$250 to $500ESTIMATE, priced 2026-09-07, compounding-pharmacy channel. Compounded tesamorelin through telehealth prescribers runs about $250 to $500 a month at the 2 mg daily dose.Branded Egrifta SV is a different order of magnitude and can reach several thousand dollars a month without coverage. Insurance usually depends on documented HIV-associated lipodystrophy and prior authorization.
Ipamorelin$25 to $60ESTIMATE, priced 2026-09-07, research-chemical channel. A 5 mg vial at $25 to $50 gives 33 to 50 doses at 100 to 150 mcg, which is about 1.1 to 1.7 months of use.Add $8 to $13 for bacteriostatic water, syringes and swabs, and add the cost of a third-party HPLC and mass-spec certificate, which the report treats as the minimum bar for this channel.
The difference$225 to $440 a month, roughly ten times the priceAn estimated $250 to $500 against $25 to $60. Over a year that is $3,000 to $6,000 against $300 to $720.That gap is the single strongest argument for ipamorelin, and it is an argument about price rather than results. Tesamorelin also behaves like chronic therapy, since benefits regress after stopping, so price the multi-year figure rather than one cycle.

When to Switch

Judge these on different calendars. Ipamorelin registers something at about 1 week, reaches full effect at about 12 weeks, and carries a 12-week assessment window. Tesamorelin takes about 4 weeks for a first noticeable change, 26 weeks for full effect, and carries a 13-week assessment window, so the earliest honest read is a quarter in and the real one is at six months.

Move from ipamorelin to tesamorelin when you have a measured target rather than a feeling: visceral fat confirmed by imaging or waist metrics, fatty liver, or an HIV lipodystrophy phenotype. Those are the endpoints Falutz 2007, Stanley 2014 and Stanley 2019 actually measured, and no amount of ipamorelin time will produce that evidence. Move the other way, from tesamorelin to ipamorelin, for cost, for the injection itself, or when the contraindication list rules tesamorelin out, which happens with active or prior malignancy, pregnancy, pituitary disruption, active diabetic retinopathy or uncontrolled glucose. Understand what you are switching to: you are trading a documented result for a cheaper compound with no human efficacy data.

Running both is the community stack, tesamorelin 1 mg plus ipamorelin 200 to 300 mcg before bed, and no RCT validates it. Whichever way you go, track IGF-1, fasting glucose and HbA1c, because both raise the same axis.

Who Should Pick What?

Adult with HIV-associated abdominal lipodystrophy

Tesamorelin

This is the labeled indication and the only place either compound has a Phase 3 approval package. Falutz 2007 and Falutz 2010 built it, and the 2025 DHHS and NIH guidelines name tesamorelin as the only US FDA-approved therapy for excessive abdominal fat in people with HIV. Ipamorelin has no standing here.

Central visceral fat confirmed by imaging or waist measurement

Tesamorelin

Body composition 7.5 against 2.0. Stanley 2014 randomized 50 people and reduced both visceral fat and liver fat over 6 months, and Badran 2026 pooled five RCTs to the same conclusion. Low-visceral-fat users have less room to benefit, which is what the report's responder profile says.

Fatty liver or early MASH under specialist care

Tesamorelin

Stanley 2019 ran 61 people with HIV-associated fatty liver over 12 months and reduced liver fat, and Fourman 2020 followed with paired liver biopsies showing changes in oxidative phosphorylation, inflammatory and fibrosis-related gene pathways. This needs liver imaging, glucose monitoring and a specialist, not a telehealth form.

Cost is the binding constraint

Ipamorelin

An estimated $25 to $60 a month against $250 to $500, roughly a tenth the price. Be clear about the trade: you are buying a compound with zero human efficacy trials for any marketed use. Sigalos 2018 reviewed the secretagogue class and called for long-term safety data including cancer endpoints.

You want better sleep and faster gym recovery

Tie

Neither is supported for this. The only sleep evidence in either record is Weikel 2003, a ghrelin infusion in 7 men that raised slow-wave sleep, and the only recovery evidence is rodent nitrogen balance and a secondary muscle-area analysis. Both are the most-marketed claims and the least-evidenced.

Active or prior cancer, pregnancy, or trying to conceive

Tie

Neither. Both raise growth hormone and IGF-1, and both reports list active malignancy and pregnancy as contraindications. Tesamorelin adds prior malignancy without oncology clearance, hypothalamic-pituitary disruption and active diabetic retinopathy. Ipamorelin adds hormone-sensitive cancer, congestive heart failure and critical illness.

You compete in tested sport

Tie

Neither, at any dose or time of year. Tesamorelin is listed under growth hormone-releasing factors and prohibited at all times, and ipamorelin's class is prohibited at all times under WADA S2. Both reports list tested sport as a contraindication.

Uncontrolled diabetes or prediabetes without monitoring

Tie

Neither until glucose is handled. The FDA label for tesamorelin warns about elevated IGF-1, glucose intolerance and fluid retention, and the ipamorelin report lists uncontrolled diabetes as a contraindication. Get fasting glucose and HbA1c on the board first.

Research Highlights

  1. Mechanism Difference

    These two are complementary rather than redundant, because they reach the same output through different receptors. Tesamorelin binds pituitary GHRH receptors and amplifies endogenous pulsatile growth hormone release, raising IGF-1 while leaving somatostatin negative feedback in place.Ipamorelin is a selective ghrelin-receptor agonist at GHS-R1a that pulses growth hormone without meaningfully raising ACTH, cortisol or prolactin, which is its whole case over GHRP-2 and GHRP-6. The tesamorelin report carries a stacked GHRH plus GHRP protocol for exactly this reason, and notes that no RCT validates it.

  2. Safety Comparison

    Ipamorelin looks milder and tesamorelin is better characterized. Ipamorelin scores 1.8 on safety risk and 1.6 on side effects, with water retention, injection-site reactions and occasional tingling reported. Raun 1998 established the selectivity that keeps cortisol and prolactin out of the picture.Tesamorelin scores 1.9 and 2.3, and its risks are documented on an FDA label: neoplasm risk, elevated IGF-1, glucose intolerance, fluid retention, hypersensitivity, injection reactions and acute critical illness. Both make active cancer an absolute contraindication, since both raise the GH and IGF-1 axis.

  3. Cost Comparison

    Tesamorelin runs an estimated $250 to $500 a month for compounded product at 2 mg daily, and branded Egrifta SV can reach several thousand without coverage. Ipamorelin runs an estimated $25 to $60 a month, since a 5 mg vial at $25 to $50 covers 33 to 50 doses at 100 to 150 mcg.Roughly a tenfold difference, and both figures are estimates priced 2026-09-07 rather than measured retail. Tesamorelin's benefits regress after discontinuation, so the honest number to plan against is the annual one, $3,000 to $6,000 against $300 to $720.

  4. Editorial Verdict

    No head-to-head trial of these two exists. Neither report's citation record contains a study comparing them, so every row here is assembled from separate evidence bases of unequal size.Take tesamorelin when you have a measured target: visceral fat, liver fat, or the HIV lipodystrophy phenotype the approval covers. Falutz 2007, Stanley 2014 and Badran 2026 measured those endpoints. Take ipamorelin when price rules tesamorelin out and you accept that its only completed human efficacy trial, Beck 2014 in postoperative ileus, missed its endpoint at p=0.15.

  5. Durability

    Tesamorelin's benefits regress once you stop. Its durability dimension scores 1.5, the lowest number on either side, and Falutz 2010 plus the 2025 DHHS and NIH guidance both record the reversal after discontinuation. It behaves like chronic therapy rather than a curative cycle.Ipamorelin scores 2.4 on durability, which reflects the absence of data more than any measured staying power. Jimenez-Reina 2002 found chronic dosing altered somatotroph response in young female rats, which is the only chronic adaptation signal in either record.

Frequently Asked Questions

Is tesamorelin better than ipamorelin?
On evidence, yes, and the identical 6.2 overall scores hide it. Tesamorelin scores higher on all 16 shared use cases, including body composition 7.5 against 2.0 and metabolic health 7.0 against 1.6, and its evidence dimension is 4.6 against 3.3. Ipamorelin's argument is price: an estimated $25 to $60 a month against $250 to $500.
Has anyone compared tesamorelin and ipamorelin head to head?
No. Neither report carries a study comparing the two, so every verdict here is built from separate evidence bases.Those bases are far apart in size. Tesamorelin has two Phase 3 HIV lipodystrophy trials, extension data, fatty-liver RCTs and a 2026 meta-analysis of five trials. Ipamorelin has one completed human efficacy trial, in postoperative ileus, which missed its endpoint.
Will ipamorelin help me sleep better?
Nothing in its record shows that. Sleep quality is the most common claim made for ipamorelin and it scores 2.8, with no human sleep trial behind it. The closest evidence is Weikel 2003, where a ghrelin infusion raised slow-wave sleep in 7 men, and that tests the receptor rather than the peptide. If sleep is your only goal, this is a weak place to spend money.
How long before I know whether either one is working?
Ipamorelin registers something at about 1 week and reaches full effect at about 12 weeks, against a 12-week assessment window. Tesamorelin takes about 4 weeks for a first change and 26 weeks for full effect, against a 13-week window. Its report puts visceral fat assessment at 13 to 26 weeks and liver fat at 6 to 12 months.
Can I stack tesamorelin and ipamorelin?
Community protocols do, at tesamorelin 1 mg plus ipamorelin 200 to 300 mcg before bed for 8 to 16 weeks, and no RCT validates the combination. The mechanistic logic is real, since one hits the GHRH receptor and the other the ghrelin receptor. Stacking tesamorelin with CJC-1295 is the redundant one, because both act at the GHRH receptor.
Which one is cheaper?
Ipamorelin, by roughly ten times. An estimated $25 to $60 a month, since a 5 mg vial at $25 to $50 covers 33 to 50 doses at 100 to 150 mcg, plus $8 to $13 for water and supplies. Tesamorelin runs an estimated $250 to $500 a month compounded, and branded Egrifta SV can reach several thousand without coverage. Both figures are estimates priced 2026-09-07.
Do the results last after I stop?
For tesamorelin, no. Its durability dimension scores 1.5, Falutz 2010 recorded regression after discontinuation, and the 2025 DHHS and NIH guidance says the same. Plan for chronic therapy or do not start.Ipamorelin scores 2.4, which reflects missing data rather than proven staying power. No human trial has measured what happens after a cycle ends.
Who should avoid both of these?
Anyone with active cancer, anyone pregnant or breastfeeding, anyone with uncontrolled diabetes, and any athlete in tested sport. Both raise growth hormone and IGF-1.Tesamorelin adds prior malignancy without oncology clearance, hypothalamic-pituitary disruption or pituitary surgery, active diabetic retinopathy, and trying to conceive. Ipamorelin adds hormone-sensitive cancer, congestive heart failure, critical illness, and any vial without a third-party certificate of analysis.

Evidence Sources

Glossary

Quick reference for the medical and technical terms used in this comparison.

GHRH Growth Hormone-Releasing Hormone
The hypothalamic signal that tells the pituitary to release growth hormone. Tesamorelin is a stabilized copy of it.
GHS-R1a Growth Hormone Secretagogue Receptor 1a
The ghrelin receptor on pituitary cells. Ipamorelin is a selective agonist at it, which is a different door into the same room.
VAT Visceral Adipose Tissue
Fat stored around the organs rather than under the skin. It is the endpoint tesamorelin's approval was built on.
IGF-1 Insulin-Like Growth Factor 1
The liver-made hormone that carries out most of growth hormone's downstream effects. Both compounds raise it, so both need it tracked.
NAFLD Non-Alcoholic Fatty Liver Disease
Fat accumulation in the liver without alcohol as the cause. Stanley 2019 tested tesamorelin against it in people with HIV.
MASH Metabolic Dysfunction-Associated Steatohepatitis
Fatty liver with inflammation and cell damage. Early MASH under specialist care is one of the tesamorelin responder profiles.
GHRP Growth Hormone-Releasing Peptide
The peptide family ipamorelin belongs to. GHRP-2 and GHRP-6 raise cortisol and prolactin where ipamorelin does not.
MCI Mild Cognitive Impairment
Measurable memory or thinking decline that stops short of dementia. Baker 2012 tested GHRH analog therapy in this group.
HPLC High-Performance Liquid Chromatography
The lab method used to confirm what is actually in a vial. For ipamorelin, a third-party HPLC and mass-spec certificate is the minimum sourcing bar.
Nick Urban

Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I've spent over a decade testing peptides on myself and screening them for clients and podcast guests

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz